Macrocyclics Overview

  • Founded
  • 1995
Founded
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A
  • Financing Rounds
  • 1

Macrocyclics General Information

Description

Manufacturer of custom chelating agents for the medical sector. The company focuses on development of new chelation chemistry platforms for advancement of diagnostic and therapeutic medicine. Its products include a line of bifunctional ligands designed specifically for bio-targeting in combination with monoclonal antibodies and peptide fragments.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Corporate Backed or Acquired
Primary Industry
Biotechnology
Other Industries
Discovery Tools (Healthcare)
Parent Company
Orano Med
Primary Office
  • 1309 Record Crossing
  • Dallas, TX 75235
  • United States
+1 (972) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Macrocyclics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Macrocyclics‘s full profile, request access.

Request a free trial

Macrocyclics Executive Team (1)

Name Title Board Seat Contact Info
Garry Kiefer Ph.D Chief Executive Officer and Director, Research and Development
To view Macrocyclics’s complete executive team members history, request access »